middle.news
INOVIQ Maps New Route for Ovarian Cancer Test After Sample Review
8:40am on Thursday 29th of October, 2026 AEDT
•
Biotechnology
Read Story
INOVIQ Maps New Route for Ovarian Cancer Test After Sample Review
8:40am on Thursday 29th of October, 2026 AEDT
Key Points
Independent review identifies pre-analytical sample variability as the primary study issue
Four-stage EXO-OC pathway targets US LDT readiness in H1 2028
A$7.650 million cash at quarter end, plus A$1.782 million post-period R&D refund
Peter Gunzburg assumes interim Executive Chair role after CEO departure
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inoviq (ASX:IIQ)
OPEN ARTICLE